1. Peptic ulcer disease [Internet]. University of Michigan Health System. cited 2007 May 4. Available from:
http://www.med.umich.edu.
2. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health. 1996. 86:200–205.
3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984. 1:1311–1315.
4. Gisbert JP, Legido J, Garcia-Sanz I, Pajares JM. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis. 2004. 36:116–120.
5. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999. 340:1888–1899.
6. Dubois F. New surgical strategy for gastroduodenal ulcer: laparoscopic approach. World J Surg. 2000. 24:270–276.
7. Testini M, Portincasa P, Piccinni G, Lissidini G, Pellegrini F, Greco L. Significant factors associated with fatal outcome in emergency open surgery for perforated peptic ulcer. World J Gastroenterol. 2003. 9:2338–2340.
8. Imhof M, Epstein S, Ohmann C, Roher HD. Duration of survival after peptic ulcer perforation. World J Surg. 2008. 32:408–412.
9. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg. 1991. 78:355–360.
10. Eachempati SR, Hydo LJ, Barie PS. Severity scoring for prognostication in patients with severe acute pancreatitis: comparative analysis of the Ranson score and the APACHE III score. Arch Surg. 2002. 137:730–736.
11. Hall JC, Hall JL. ASA status and age predict adverse events after abdominal surgery. J Qual Clin Pract. 1996. 16:103–108.
12. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005. 92:1099–1102.
13. Taha AS, Angerson WJ, Prasad R, McCloskey C, Gilmour D, Morran CG. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008. 28:878–885.
14. Rahman MM, Islam MS, Flora S, Akhter SF, Hossain S, Karim F. Mortality in perforated peptic ulcer patients after selective management of stratified poor risk cases. World J Surg. 2007. 31:2341–2346.
15. Noguiera C, Silva AS, Santos JN, Silva AG, Ferreira J, Matos E, et al. Perforated peptic ulcer: main factors of morbidity and mortality. World J Surg. 2003. 27:782–787.
16. Jones HJ, de Cossart L. Risk scoring in surgical patients. Br J Surg. 1999. 86:149–157.
17. Boey J, Wong J, Ong GB. A prospective study of operative risk factors in perforated duodenal ulcers. Ann Surg. 1982. 195:265–269.
18. Chan WH, Wong WK, Khin LW, Soo KC. Adverse operative risk factors for perforated peptic ulcer. Ann Acad Med Singapore. 2000. 29:164–167.
19. Kim KY, Park YK, Choi CR. A clinical analysis of the complicated duodenal ulcers. J Korean Surg Soc. 1992. 43:30–41.
20. Seo JH, Park HK, Park YH, Lee HK, Lee WG, Cho SY, et al. Prognostic factors in duodenal ulcer perforation. J Korean Surg Soc. 2001. 60:425–431.
21. Blomgren LG. Perforated peptic ulcer: long-term results after simple closure in the elderly. World J Surg. 1997. 21:412–415.
22. Tsugawa K, Koyanagi N, Hashizume M, Tomikawa M, Akahoshi K, Ayukawa K, et al. The therapeutic strategies in performing emergency surgery for gastroduodenal ulcer perforation in 130 patients over 70 years of age. Hepatogastroenterology. 2001. 48:156–162.